Cellular Immunotherapy for Hematological Malignancies and Solid Tumors is under clinical development by Cell Source and currently in Phase II for Blood Cancer. According to GlobalData, Phase II drugs for Blood Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy for Hematological Malignancies and Solid Tumors’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cellular Immunotherapy for Hematological Malignancies and Solid Tumors overview

Cellular immunotherapy for hematological malignancies is under development for the treatment of non Hodgkin lymphoma, multiple myeloma, blood cancer and solid tumors. The therapeutic candidate is a combination of veto cell (donor derived cells) and with CAR-T cell therapy, a CD8 central memory anti-3rd party T-cell infusions derived from the patient’s own blood are combined with cell therapy. This therapy is developed based on Veto-Cell immune system management technology.

Cell Source overview

Cell Source is a biotechnology company. It offers development of cell therapy treatments based on the management of immune tolerance. The company’s Veto Cells are white blood cells taken from either the patient or a healthy third-party donor and used to prevent post-transplant infections resulting from common viruses that cause post-transplant complications and mortality. Cell Source also offers anti-rejection Veto Cell, Veto Cell genetically modified cells for allogeneic treatment and Veto Cell for non-malignant disease. The company patented Veto-Cell technology represents a breakthrough in immune system management safe and selective tolerizing of immune response, Anti-rejection Veto Cells enable the selective attenuation of immune system response and others. The company provides revolutionizing transplantation and cancer treatment utilizing immune tolerance technology. Cell Source is headquartered in New York, the US.

For a complete picture of Cellular Immunotherapy for Hematological Malignancies and Solid Tumors’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.